A research team at NOVA University Lisbon performs a comprehensive scoping review of supervised ML frameworks—including XGBoost, Random Forest, and LASSO—leveraging electronic health record datasets to predict 30- and 90-day heart failure hospitalisation and readmission risks, emphasizing ensemble methods and the current lack of economic impact assessments.
Key points
- Ensemble algorithms (XGBoost, CATBOOST) achieved top predictive performance with mean AUC up to 0.88 for unspecified-period heart failure risk.
- EHR-derived datasets across 13 countries provided clinical, demographic, and utilization variables for 30- and 90-day risk modelling.
- No reviewed studies included economic evaluations, indicating a critical gap for assessing cost-effectiveness before clinical deployment.
Why it matters: This synthesis underscores ensemble ML's potential to refine heart failure risk stratification and highlights gaps in cost-effectiveness evaluations crucial for clinical adoption.
Q&A
- What is a scoping review?
- How does AUC measure predictive performance?
- What are ensemble learning methods?
- Why are economic analyses important in ML healthcare studies?